Brief: Stoke Therapeutics Plans To Initiate Phase 3 Study Of Zorevunersen To Treat Dravet Syndrome On Alignment With Global Regulatory Agencies
07/01/2025 12:21
Jan 7 (Reuters) - Stoke Therapeutics Inc STOK.O :
* STOKE THERAPEUTICS ANNOUNCES ALIGNMENT WITH GLOBAL
REGULATORY
AGENCIES AND PLANS TO INITIATE A PHASE 3 STUDY OF ZOREVUNERSEN
AS POTENTIALLY THE FIRST DISEASE-MODIFYING MEDICINE FOR THE
TREATMENT OF DRAVET SYNDROME
* STOKE THERAPEUTICS : FDA BREAKTHROUGH THERAPY DESIGNATION
POSITIONS ZOREVUNERSEN ON EFFICIENT DEVELOPMENT PATH; PLANS TO
START PHASE 3 IN MID-2025
Source text: ID:nBw284W8Ga
Further company coverage: STOK.O
((Reuters.Brief@thomsonreuters.com))
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics